Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>EULAR</strong> <strong>2023</strong><br />
Congress Preview<br />
Chair’s Introduction<br />
Dear Colleagues,<br />
Welcome to the <strong>Lupus</strong> Forum <strong>EULAR</strong> <strong>2023</strong> Congress Preview.<br />
This brochure provides you with all you need to know about<br />
the lupus content at <strong>EULAR</strong> this year, including the Scientific<br />
Sessions, Oral Abstract Presentations, and Poster Sessions of<br />
interest. I’ve highlighted some Chair’s picks of the key content –<br />
I hope you find them useful!<br />
Wednesday afternoon sees the scientific session Everything is<br />
difficult to treat?, featuring a presentation from Professor David<br />
Isenberg on lupus. This promises to be a really interesting session<br />
and one not to miss. Also on Wednesday, there’s an Oral Abstract<br />
Session on GC to new therapies, which includes abstracts on<br />
real-world oral glucocorticoid use from the LUPIN-F study<br />
(OP0046), low disease activity attainment for anifrolumab in the<br />
TULIP long term extension study (OP0051), and predictors of<br />
renal flares in the belimumab clinical trial programme (OP0052).<br />
On Thursday, the Oral Abstract Session The future perspectives in<br />
the treatment of SLE & Sjögren’s features a number of abstracts of<br />
interest focusing on the treatment of SLE, including phase 3 results<br />
for telitacicept (OP0137), phase 2 results for combined elsubrutinib<br />
and upadacitinib therapy (OP0139), phase 1 results of efavaleukin<br />
alfa, a novel IL-2 mutein (OP0140), and the long term safety and<br />
efficacy results of CAR-T cell therapy (OP0141). The focus on new<br />
data for SLE treatments continues on Thursday afternoon, with<br />
the Poster Session A novel journey into SLE, Sjögren and APS.<br />
I recommend you make time to see the posters on safety and<br />
tolerability of ALPN-303 (POS0114), the post hoc analysis on the<br />
phase 2 data on dapirolizumab pegol (POS0115) and safety and<br />
efficacy data on subcutaneous ianalumab (POS0120).<br />
On Friday there are three posters of particular interest in Poster<br />
View 4, the first focusing on zetomipzomib for the treatment of lupus<br />
nephritis (POS1128), the second presenting biomarker analysis of<br />
the SLEek study (POS1133), and finally, efficacy of cenerimod in<br />
patients with high IFN-1 gene expression signature (POS1147).<br />
Saturday features a presentation from Professor Dimitrios<br />
Boumpas on the <strong>EULAR</strong> recommendations on the<br />
management of lupus. This will be a great opportunity to<br />
find out the most up-to-date information for clinical practice.<br />
We add new content to the <strong>Lupus</strong> Forum regularly, with<br />
monthly slide summaries of key publications, monthly podcasts<br />
discussing recent advances, and congress materials such as<br />
these. You can register for updates at lupus-forum.com or keep<br />
up to date by following us on Twitter @<strong>Lupus</strong>Forum and on<br />
LinkedIn by searching “<strong>Lupus</strong> Forum”.<br />
I hope you find our selection of highlights useful and that you<br />
enjoy the meeting in Milan!<br />
Kind regards,<br />
Key <strong>Lupus</strong> Content<br />
Wednesday, 31 May <strong>2023</strong><br />
14:15–<br />
15:30<br />
14:15–<br />
15:30<br />
14:15–<br />
15:30<br />
OP0011<br />
16:30–<br />
18:00<br />
OP0046<br />
OP0047<br />
OP0048<br />
Everything is Difficult to Treat?<br />
Chairs: László Czirják and Jacob M van Laar<br />
D2T <strong>Lupus</strong><br />
David Isenberg<br />
Precision Medicine in SLE: Where Are We?<br />
Chairs: Dimitrios Boumpas and<br />
Jose M Pego-Reigosa<br />
<strong>Lupus</strong> classification and diagnosis still based on<br />
clinical manifestations<br />
Martin Aringer<br />
Precision medicine in SLE: What is the role of drugs<br />
mechanisms of action in the identification of the<br />
right therapy?<br />
Edward Vital<br />
Epigenetics in Chronic Inflammation<br />
Chairs: Gisela Orozco and Carl Goodyear<br />
Epitranscriptome editing represents an additional layer<br />
of immune-related epigenetic memory of monocytes<br />
in human systemic lupus erythematosus (SLE)<br />
Aggelos Banos<br />
GC to New Therapies<br />
Chairs: Isabelle Peene and Hendrika Bootsma<br />
Real-world oral glucocorticoid use in systemic<br />
lupus erythematosus: A nation-wide populationbased<br />
study using the French National Medicoadministrative<br />
database (LUPIN-F study)<br />
Laurent Arnaud<br />
Withdrawal of maintenance glucocorticoid versus<br />
other immunosuppressants among patients with<br />
systemic lupus erythematosus in long term clinical<br />
remission: Interim analysis of a non-inferiority<br />
randomised controlled trial<br />
Aishwarya Gopal<br />
Risk of flare and damage accrual after tapering<br />
glucocorticoids in serologically active clinically<br />
quiescent patients with systemic lupus erythematosus<br />
Yasuhiro Katsumata<br />
Key:<br />
CP<br />
Chair’s pick<br />
CP<br />
Ed Vital<br />
Chair of the <strong>Lupus</strong> Forum Steering Committee<br />
Associate Professor, University of Leeds<br />
Scientific session<br />
Poster session<br />
Oral abstracts<br />
Abstract session<br />
Developed under<br />
the auspices of:<br />
Supported with<br />
educational<br />
grants from:
Key: CP Chair’s pick Scientific session Oral abstracts Poster session Abstract session<br />
OP0050<br />
Increased IFITM gene-signatures in age-associated<br />
B and plasma cells define non-response to<br />
mycophenolate mofetil in systemic lupus erythematosus<br />
Daniel Toro-Domínguez<br />
POS0115<br />
Dapirolizumab pegol efficacy by subgroups in<br />
patients with systemic lupus erythematosus:<br />
A post hoc analysis of phase 2 clinical trial data<br />
Anca Askanase<br />
CP<br />
OP0051<br />
OP0052<br />
<strong>Lupus</strong> low disease activity state attainment<br />
in the phase 3 placebo-controlled TULIP<br />
long-term extension trial of anifrolumab<br />
Eric F Morand<br />
Predictors of renal flares in systemic lupus<br />
erythematosus: A post-hoc analysis of four<br />
phase III clinical trials of belimumab<br />
Alvaro Gomez<br />
CP<br />
CP<br />
POS0120<br />
14:15–<br />
15:00<br />
Safety and efficacy of subcutaneous (s.c.)<br />
dose ianalumab (VAY736; anti-BAFFR mAb)<br />
administered monthly over 28 weeks in patients<br />
with systemic lupus erythematosus (SLE)<br />
Josefina Cortés-Hernández<br />
How to Treat <strong>Lupus</strong><br />
Chairs: Mariana Kaplan and Andrea Doria<br />
CP<br />
OP0053<br />
Efficacy and safety of baricitinib in patients with<br />
active lupus nephritis: A double-blind, randomized,<br />
placebo-controlled phase 3 trial<br />
Manal Hassanien<br />
How to treat lupus<br />
Dimitrios Boumpas<br />
Thursday, 01 June <strong>2023</strong><br />
10:30–<br />
12:00<br />
OP0136<br />
OP0137<br />
OP0139<br />
OP0140<br />
OP0141<br />
12:00–<br />
13:30<br />
POS0112<br />
POS0114<br />
The Future Perspectives in the Treatment<br />
of SLE & Sjögren’s<br />
Chairs: Ronald van Vollenhoven and<br />
Nathalie Costedoat-Chalumeau<br />
Metabolomic serum profiling identifies metabolites<br />
linked to kidney damage which are modulated by<br />
anifrolumab in a phase 2 trial in lupus nephritis<br />
David Jayne<br />
Efficacy and safety of telitacicept, a novel<br />
BLyS/APRIL dual inhibitor, in patients with<br />
systemic lupus erythematosus: A phase 3,<br />
randomized, placebo-controlled 52-week study<br />
Ronald van Vollenhoven<br />
Efficacy and safety of ABBV-599 high dose<br />
(elsubrutinib 60 mg and upadacitinib 30 mg)<br />
and upadacitinib monotherapy for the treatment<br />
of systemic lupus erythematosus: A phase 2,<br />
double-blind, placebo-controlled trial<br />
Joan T Merrill<br />
Regulatory T cell defects in SLE and therapy<br />
with a novel IL-2 mutein: Phase 1 clinical<br />
results with efavaleukin alfa<br />
Richard Furie<br />
Long term safety and efficacy of CAR-T CP<br />
cell treatment in refractory systemic lupus<br />
erythematosus – Data from the first seven patients<br />
Georg Schett<br />
A Novel Journey into SLE, Sjögren and APS<br />
Chairs: Isabelle Peene and Helena Achten<br />
Deucravacitinib reduces interferons, B-cell pathways,<br />
and serological biomarkers of systemic lupus disease<br />
activity: Pharmacodynamic analysis from the phase 2<br />
PAISLEY study<br />
Ian M Catlett<br />
A placebo-controlled phase 1 study in healthy<br />
adult volunteers of the safety, tolerability,<br />
pharmacokinetics, and pharmacodynamics<br />
of ALPN-303, a potent dual BAFF/APRIL<br />
antagonist, for the treatment of systemic<br />
lupus erythematosus<br />
Stacey R Dillon<br />
CP<br />
CP<br />
CP<br />
CP<br />
Friday, 02 June <strong>2023</strong><br />
09:30–<br />
10:30<br />
POS1125<br />
POS1126<br />
POS1128<br />
POS1129<br />
POS1132<br />
POS1133<br />
POS1134<br />
POS1136<br />
POS1137<br />
POS1138<br />
Poster View 4<br />
Hydroxychloroquine use in pregnant women with<br />
systemic lupus erythematosus and major congenital<br />
malformations in the offspring<br />
Ngoc V Nguyen<br />
Therapeutic range of hydroxychloroquine blood levels<br />
can reduce odds of high lupus disease activity<br />
Shivani Garg<br />
Zetomipzomib (KZR-616) treatment results<br />
in clinically meaningful renal responses in<br />
patients with lupus nephritis<br />
Amit Saxena<br />
In vitro evidence demonstrates that afimetoran<br />
(BMS-986256), an equipotent TLR7/8 dual antagonist,<br />
has steroid-sparing potential in the clinic<br />
Qihong Zhao<br />
Hydroxychloroquine, which regulates IFN, is highly<br />
effective in SLE with elevated serum S100 protein<br />
Risa Wakiya<br />
Treatment of systemic lupus erythematosus<br />
patients with upadacitinib results in the<br />
coordinated inhibition of type 1 IFN-related<br />
biomarkers: Biomarker analysis of the<br />
M19-130 (SLEek) phase 2 study<br />
Joan T Merrill<br />
Novel approach to treat systemic lupus<br />
erythematosus, by targeting the “root cause”, B cells<br />
and plasma cells, using BCMA-CD19 compound CAR<br />
Greg Deener<br />
Disease-modifying effect and long-term safety data<br />
of belimumab in patients with SLE: A single centre<br />
retrospective analysis<br />
Masato Okada<br />
Pharmacokinetics and exposure-response relationships<br />
of upadacitinib or elsubrutinib alone or in combination<br />
(ABBV-599) in systemic lupus erythematosus<br />
Mohamed-Eslam Mohamed<br />
Sirolimus versus mycophenolate mofetil for the<br />
treatment of lupus nephritis: Results from a real-world<br />
CSTAR cohort study<br />
Wei Bai<br />
CP<br />
CP
Key: CP Chair’s pick Scientific session Oral abstracts Poster session Abstract session<br />
POS1141<br />
POS1143<br />
POS1145<br />
POS1147<br />
POS1149<br />
POS1150<br />
POS1151<br />
POS1152<br />
POS1154<br />
POS1155<br />
POS1156<br />
10:30–<br />
12:00<br />
OP0226<br />
OP0227<br />
Subtherapeutic hydroxychloroquine concentration<br />
is associated with increased disease activity and<br />
greater organ damage during 5-year follow-up in<br />
patients with systemic lupus erythematosus<br />
Shin-Seok Lee<br />
Urinary CD163 predicts complete renal response with<br />
zetomipzomib treatment in the open-label mission<br />
phase 2 study in patients with lupus nephritis<br />
Joan T Merrill<br />
Factors associated with survival and discontinuation of<br />
antimalarial agents in systemic lupus erythematosus:<br />
Results from a Swedish longitudinal registry<br />
Tomas Walhelm<br />
Efficacy of cenerimod in patients with high<br />
IFN-1 gene expression signature and high<br />
anti-dsDNA antibody levels: Post-hoc analysis<br />
from a phase 2 study<br />
Anca Askanase<br />
Comparison of the efficacy and safety of telitacicept<br />
versus belimumab in patients with systemic lupus<br />
erythematosus in real clinical practice: Analyses<br />
with propensity score-based inverse probability of<br />
treatment weighting<br />
Huizhi Jin<br />
Ultrasound-detected erosions could predict the efficacy<br />
of belimumab in articular systemic lupus erythematosus<br />
Giovanni Orsolini<br />
Therapeutic drug monitoring of azathioprine and<br />
tacrolimus in SLE pregnancies: Preliminary results<br />
from the LEGACY cohort<br />
Reem Farhat<br />
Attainment of <strong>EULAR</strong>/ERA-EDTA treatment targets<br />
in the first year in lupus nephritis: A multicenter<br />
observational study<br />
Maria Pappa<br />
Pre-treatment differentially expressed metagenes<br />
characterize systemic lupus patients who<br />
subsequently achieve clinical response to belimumab<br />
Joan T Merrill<br />
Impact of hydroxychloroquine on interferon pathway<br />
expression of SLE phenotypic subsets in the absence<br />
of background medications<br />
Colin Mowery<br />
Predictors of de novo renal flares in systemic lupus<br />
erythematosus – time to revisit belimumab dose<br />
for extra-renal disease? Results from five phase III<br />
clinical trials of belimumab<br />
Ioannis Parodis<br />
Updates on Management and Outcomes<br />
in SLE And Sjögren Syndrome<br />
Chairs: Marta Mosca and<br />
Cristiana Sieiro Santos<br />
Attainment of lupus low disease activity state<br />
exclusive of remission is protective against adverse<br />
outcomes in systemic lupus erythematosus<br />
Eric F Morand<br />
Improvements and challenges of systemic lupus<br />
erythematosus associated pulmonary arterial<br />
hypertension: A 10-year multicenter cohort study<br />
Xingbei Dong<br />
CP<br />
OP0228<br />
OP0229<br />
OP0230<br />
12:00–<br />
13:30<br />
POS0134<br />
POS0136<br />
POS0137<br />
POS0138<br />
12:00–<br />
13:30<br />
POS0167<br />
POS0168<br />
POS0169<br />
POS0170<br />
Coexisting tubulointerstitial inflammation and<br />
damage is a risk factor for chronic kidney disease<br />
in patients with lupus nephritis: Results from the<br />
KORNET registry<br />
Dong-Jin Park<br />
Changes in the causes and predictors of lupus<br />
mortality in Spain through the last decades:<br />
Data from the RELESSER Registry<br />
Clara Moriano<br />
Using an innovative digital tool for the assessment<br />
and personalized recommendations to cope<br />
with fatigue in systemic lupus erythematosus:<br />
The LEAF study<br />
Lou Kawka<br />
What’s New in Paediatric RMDs?<br />
Chairs: Raquel Campanilho-Marques and<br />
Annet van Royen<br />
Learning from longitudinal data in childhood onset<br />
systemic lupus erythematosus: Which biomarkers<br />
have predictive value for endothelial involvement?<br />
Sandy Bergkamp<br />
Performance of the American College of<br />
Rheumatology-1997, the Systemic <strong>Lupus</strong><br />
International Collaborating Clinics-2012, and the<br />
European League Against Rheumatism-2019 criteria<br />
for childhood-onset systemic lupus erythematosus:<br />
A southeast Asia validation study<br />
Kai Liang Teh<br />
Serious infections in juvenile SLE: Incidence,<br />
predictors and impact on long term outcomes in a<br />
south Asian cohort<br />
Rudrarpan Chatterjee<br />
Efficacy and safety of belimumab in adults with<br />
childhood-onset systemic lupus erythematosus:<br />
Preliminary results from a prospective<br />
observational study<br />
Despoina Dimopoulou<br />
Systemic <strong>Lupus</strong> Erythematosus, Sjögren’s<br />
Syndrome and Anti-Phospholipid Syndrome:<br />
Clinical Aspects<br />
Chairs: Marta Mosca and Sarah Dyball<br />
The antimalarial protective effect and a clear cut-off<br />
point for steroid cumulative dose associated with<br />
damage accrual on a 10-year follow-up systemic<br />
lupus erythematosus cohort<br />
Ricardo Montes<br />
Impact of the hydroxychloroquine level on the<br />
ECQ QT interval in patients with systemic rheumatic<br />
autoimmune diseases: A real-life study<br />
Carmen Raya-Santos<br />
Predictors of first hospitalizations due to<br />
disease activity and infections in systemic lupus<br />
erythematosus patients<br />
Guillermo Pons-Estel<br />
All-cause mortality and the incidence of cancer in<br />
patients with moderate-to-severe SLE: Results from<br />
the British Isles <strong>Lupus</strong> Assessment Group Biologics<br />
Registry (BILAG-BR)<br />
Mia Rodziewicz
Key: CP Chair’s pick Scientific session Oral abstracts Poster session Abstract session<br />
Saturday, 03 June <strong>2023</strong><br />
09:00–<br />
10:15<br />
LB0004<br />
LB0005<br />
10:00–<br />
11:30<br />
POS0289<br />
POS0290<br />
POS0291<br />
POS0296<br />
12:00–<br />
13:15<br />
Late-breaking Oral Abstract Session<br />
Chairs: Caroline Ospelt and Christian Dejaco<br />
Paediatric Systemic <strong>Lupus</strong> Erythematosus (pSLE)<br />
patient stratification and high-performance serum<br />
biomarkers identified responders to statin and<br />
patients with high cardiovascular risk in the APPLE<br />
trial (Atorvastatin for Atherosclerosis Progression in<br />
Paediatric Systemic <strong>Lupus</strong> Erythematosus)<br />
Coziana Ciurtin<br />
Rituximab Objective Outcome measures Trial<br />
in SLE (ROOTS): A double-blind randomised<br />
placebo-controlled feasibility trial<br />
Khaled Mahmoud<br />
Molecular and Metabolic Biomarkers of<br />
Activity, Severity and Response to Treatment<br />
Chairs: George Bertsias and Aggelos Banos<br />
Serum soluble mediator signatures of lupus nephritis<br />
histological features and response to treatment<br />
Andrea Fava<br />
Novel anti-mitochondrial antibodies identify<br />
patients with propensity to thrombogenesis in<br />
systemic lupus erythematosus<br />
Marina Barguil Macedo<br />
Identification of subsets of SLE patients<br />
responsive to iberdomide by transcriptomic<br />
analysis of baseline samples<br />
Peter Lipsky<br />
Gene expression in SLE patients, dominated by<br />
unique B cell profiles, distinguishes those with<br />
clinical improvement from abatacept<br />
Kevin Thomas<br />
<strong>EULAR</strong> Recommendations Session<br />
Chairs: Robert B M Landewé and Uta Kiltz<br />
<strong>EULAR</strong>-Recommendations on the management<br />
of lupus<br />
Dimitrios Boumpas<br />
Abstract Sessions<br />
SLE, Sjön’s and APS –<br />
Clinical aspects (other than treatment)<br />
AB0575<br />
Impact of patient-reported disease activity on<br />
health-related quality of life (HRQoL) in systemic<br />
lupus erythematosus (SLE) patients. Data from the<br />
ALMENARA lupus cohort<br />
Manuel F Ugarte-Gil<br />
SLE, Sjön’s and APS – Treatment<br />
AB0514<br />
AB0518<br />
AB0519<br />
AB0521<br />
AB0534<br />
AB0538<br />
AB0552<br />
AB0556<br />
Laboratory marker improvements following long-term<br />
treatment with anifrolumab in adults with systemic<br />
lupus erythematosus in the placebo-controlled TULIP<br />
extension study<br />
Edward Vital<br />
Effect of litifilimab on type I interferon (IFN) biomarkers<br />
in patients with systemic lupus erythematosus (SLE)<br />
or cutaneous lupus erythematosus (CLE): Result of<br />
the LILAC phase 2 study<br />
Richard Furie<br />
Long-term safety of belimumab among adult<br />
patients with SLE: Pooled data from three open-label<br />
extension studies over 11+ years<br />
Aneela Mian<br />
Identification of an interferon 5-gene signature score<br />
as a pharmacodynamic and potential predictive<br />
biomarker for deucravacitinib treatment in a phase 2<br />
trial in patients with systemic lupus erythematosus<br />
Chun Wu<br />
Treating systemic lupus erythematosus in the 21st<br />
century: Combining rituximab with belimumab<br />
Bakytsholpan Issayeva<br />
Low-dose belimumab and antimalarial agents prevent<br />
renal flares in systemic lupus erythematosus: Results<br />
from four randomised clinical trials<br />
Alvaro Gomez<br />
Effect of belimumab in patients with systemic lupus<br />
erythematosus treated with minimal or no steroid<br />
Yeo-Jin Lee<br />
Off label use of targeted therapies in SLE: Single<br />
center experience from the ATTIKON lupus cohort<br />
Georgia-Savina Moysidou<br />
Industry Sessions<br />
Satellite Symposia<br />
Wednesday,<br />
31 May <strong>2023</strong><br />
Thursday,<br />
01 June <strong>2023</strong><br />
Friday,<br />
02 June <strong>2023</strong><br />
Friday,<br />
02 June <strong>2023</strong><br />
18:30–<br />
19:45<br />
08:15–<br />
09:30<br />
08:15–<br />
09:30<br />
08:15–<br />
09:30<br />
Consult the Experts<br />
Thursday,<br />
01 June <strong>2023</strong><br />
Thursday,<br />
01 June <strong>2023</strong><br />
09:45–<br />
10:15<br />
15:00–<br />
15:30<br />
GlaxoSmithKline – Is there a<br />
“window of opportunity” in SLE?<br />
AstraZeneca – Anifrolumab in SLE –<br />
perspectives from the real world<br />
GlaxoSmithKline – How can we tackle<br />
the early drivers of organ damage and<br />
excess mortality in SLE?<br />
Otsuka – <strong>Lupus</strong> nephritis: Can we talk<br />
about a change of perspective today?<br />
GlaxoSmithKline – Is there a<br />
“window of opportunity” in SLE?<br />
GlaxoSmithKline – Can disease<br />
modification help us tackle organ<br />
damage and excess mortality in SLE?<br />
Developed under<br />
the auspices of:<br />
Supported with<br />
educational<br />
grants from:
Change language